Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03788434 · ClinicalTrials.gov registry record · Phase 2

Phase 2 Study of VE303 for Prevention of Recurrent Clostridioides Difficile Infection

A Phase 2 study, sponsored by Vedanta Biosciences.

Completed
Registry status
Phase 2
Development phase
79
Enrollment target

NCT03788434: Completed Phase 2 study, sponsored by Vedanta Biosciences.

NCT03788434 is a Phase 2 study that has completed, run by Vedanta Biosciences. The registered enrollment target is 79 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (41% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03788434, a Phase 2 study, has completed, sponsored by Vedanta Biosciences.

COMPLETED
Registry status
Phase 2
Development phase
79 participants
Enrollment target

Study Summary

This study evaluated the safety and efficacy of VE303 for participants with primary C. difficile infection (pCDI) at high risk for recurrence or subjects with recurrent C. difficile infections (rCDI).

Primary Outcome

Percentage of participants with toxin-positive, laboratory-confirmed, or clinically diagnosed and treated CDI recurrence before or at Week 8 (i.e., 8 weeks after the first dose of study treatment).

Interventions

  • DRUG Placebo
  • DRUG VE303

Trial Details

FieldValue
Enrollment Target 79 participants
Start Date 2019-02-08
Est. Completion 2021-09-15
Phase Phase 2
Vedanta Biosciences

5 total trials

What the finished NCT03788434 record still lists

NCT03788434 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 79 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (41% lower).

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT03788434 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT03788434 about?

NCT03788434 is a clinical study titled "Phase 2 Study of VE303 for Prevention of Recurrent Clostridioides Difficile Infection". This study evaluated the safety and efficacy of VE303 for participants with primary C. difficile infection (pCDI) at high risk for recurrence or subjects with recurrent C. difficile infections (rCDI).

What is the current status of trial NCT03788434?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 79 participants. The study started on 2019-02-08. Estimated completion is 2021-09-15.

What interventions are being tested in trial NCT03788434?

The interventions under investigation include: Placebo (DRUG), VE303 (DRUG).

Who is sponsoring clinical trial NCT03788434?

This trial is sponsored by Vedanta Biosciences, which has 5 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT03788434's enrollment target sits among peer trials

79 884th of 2000 higher than 1,117 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05798897 · 79 participants · Phase 1

    Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma

  • NCT06042439 · 79 participants · NA

    AM vs PM Exercise Training

  • NCT06223555 · 79 participants · NA

    Variability In Mixed Meal Tests: Fixed Versus Adjusted to Energy Needs Caloric Dose

  • NCT01243931 · 80 participants · NA

    Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03788434, the US trial registry maintained by the National Library of Medicine. NCT03788434 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.